CoaguSense

Executive Summary

CoaguSense is a US-based diagnostics company that has developed the Coag-Sense® PT/INR Monitoring System, a point-of-care device for measuring prothrombin time and International Normalized Ratio in patients on warfarin anticoagulation therapy. The system is designed for use in laboratories, clinics, and home self-testing, offering rapid and accurate results. With the growing prevalence of atrial fibrillation and other conditions requiring anticoagulation, the demand for convenient INR monitoring is increasing. CoaguSense's device competes with established players like Roche's CoaguChek and Abbott's i-STAT, but differentiates through ease of use and potentially lower cost. The company is privately held and has been operating since 2008, suggesting a mature product with existing market traction. Although financial details are scarce, the company's focus on a specific, chronic patient population positions it for steady adoption, particularly as telehealth and home monitoring trends accelerate. Key risks include competition and regulatory changes.

Upcoming Catalysts (preview)

• Q4 2026FDA Clearance for Expanded Indications or Next-Generation System50% success
• Q1 2027Strategic Partnership or Distribution Agreement with Major Healthcare Provider30% success
• Q2 2027Publication of Real-World Evidence Study Demonstrating Clinical Utility in Home Settings40% success